Skip to content

Individualized Transcranial Direct Current Stimulation for Improving Post-stroke Depression: A Prospective, Randomized, Double-blind, Multicenter Clinical Controlled Trial

Individualized Transcranial Direct Current Stimulation for Improving Post-stroke Depression: A Prospective, Randomized, Double-blind, Multicenter Clinical Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118413
Enrollment
Unknown
Registered
2026-02-05
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke Depression

Interventions

Experimental group:Individualized tDCS, stimulation target, current intensity, electrode configuration, etc. are customized individually, and verified by fNIRS before each treatment to ensure effectiv
Control Group:The general clinical standardization scheme was adopted: the electrode configuration was F3 point on the left side of the anode (International 10-20 system), the shoulder peak on the rig

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Meeting the diagnostic criteria of *Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2022* (first-episode ischemic/hemorrhagic stroke), with onset time of 3-6 months; 2.Meeting the diagnostic criteria for depressive disorder in DSM-5, with a Hamilton Depression Rating Scale (HAMD-17) score >= 17; 3.Being able to cooperate with fNIRS detection and tDCS treatment, with expected follow-up compliance >= 80%; 4.Signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Comorbid with other major mental disorders such as bipolar affective disorder and schizophrenia; 2.Severe cognitive impairment (score of Mini-Mental State Examination (MMSE) < 24); 3. Contraindications to tDCS such as intracranial metal implants (e.g., cardiac pacemaker, cochlear implant) and history of epilepsy; 4.Adjustment of antidepressant dosage or addition of new psychotherapy in the past month; 5.Severe underlying diseases such as severe hepatic, renal or cardiac insufficiency, and malignant tumor.

Design outcomes

Primary

MeasureTime frame
The Hamilton Depression Scale Score;

Secondary

MeasureTime frame
Montgomery Depression Scale Score;Hamilton Anxiety Scale Score;National Institute of Health stroke scale Score;Modified Barthel Index;Changes in core fNIRS indicators;Changes in Quality of Life Scores (SF-36 Scale);

Countries

China

Contacts

Public ContactWeiming Sun

The First Affiliated Hospital of Nanchang University

sunweiming08@126.com+86 132 9141 9434

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026